381 related articles for article (PubMed ID: 18804555)
1. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
[TBL] [Abstract][Full Text] [Related]
2. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ; Chalasani N; Kowdley KV; McCullough A; Diehl AM; Bass NM; Neuschwander-Tetri BA; Lavine JE; Tonascia J; Unalp A; Van Natta M; Clark J; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
N Engl J Med; 2010 May; 362(18):1675-85. PubMed ID: 20427778
[TBL] [Abstract][Full Text] [Related]
4. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
Lavine JE; Schwimmer JB; Molleston JP; Scheimann AO; Murray KF; Abrams SH; Rosenthal P; Sanyal AJ; Robuck PR; Brunt EM; Unalp A; Tonascia J;
Contemp Clin Trials; 2010 Jan; 31(1):62-70. PubMed ID: 19761871
[TBL] [Abstract][Full Text] [Related]
5. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
[TBL] [Abstract][Full Text] [Related]
6. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
[TBL] [Abstract][Full Text] [Related]
7. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
9. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
10. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
Said A; Akhter A
Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
[TBL] [Abstract][Full Text] [Related]
11. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
12. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).
Albert SG; Wood EM
J Diabetes Complications; 2024 Jul; 38(7):108777. PubMed ID: 38788522
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
Boettcher E; Csako G; Pucino F; Wesley R; Loomba R
Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
[TBL] [Abstract][Full Text] [Related]
14. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
Lavine JE; Schwimmer JB; Van Natta ML; Molleston JP; Murray KF; Rosenthal P; Abrams SH; Scheimann AO; Sanyal AJ; Chalasani N; Tonascia J; Ünalp A; Clark JM; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
JAMA; 2011 Apr; 305(16):1659-68. PubMed ID: 21521847
[TBL] [Abstract][Full Text] [Related]
15. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
[TBL] [Abstract][Full Text] [Related]
16. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Lomonaco R; Sunny NE; Bril F; Cusi K
Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
